Vellenga, Edo; van Putten, Wim; Ossenkoppele, Gert J; Verdonck, Leo F; Theobald, Matthias; Cornelissen, Jan J; Huijgens, Peter C; Maertens, Johan; Gratwohl, Alois; Schaafsma, Ron; Schanz, Urs; Graux, Carlos; Schouten, Harry C; Ferrant, Augustin; Bargetzi, Mario; Fey, Martin F; Löwenberg, Bob; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), ; Swiss Group for Clinical Cancer Research Collaborative Group (SA, (2011). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, 118(23), pp. 6037-42. Washington, D.C.: American Society of Hematology 10.1182/blood-2011-07-370247
Full text not available from this repository. (Request a copy)We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high-dose cyclophosphamide and busulfan. Of patients randomized (chemotherapy, n = 259; ASCT, n = 258), more than 90% received their assigned treatment. The 2 groups were comparable with regard to prognostic factors. The ASCT group showed a markedly reduced relapse rate (58% vs 70%, P = .02) and better relapse-free survival at 5 years (38% vs 29%, P = .065, hazard ratio = 0.82; 95% confidence interval, 0.66-1.1) with nonrelapse mortality of 4% versus 1% in the chemotherapy arm (P = .02). Overall survival was similar (44% vs 41% at 5 years, P = .86) because of more opportunities for salvage with second-line chemotherapy and stem cell transplantation in patients relapsing on the chemotherapy arm. This large study shows a relapse advantage for ASCT as postremission therapy but similar survival because more relapsing patients on the chemotherapy arm were salvaged with a late transplantation for relapse. This trial is registered at www.trialregister.nl as #NTR230 and #NTR291.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Fey, Martin |
ISSN: |
0006-4971 |
Publisher: |
American Society of Hematology |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:23 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.1182/blood-2011-07-370247 |
PubMed ID: |
21951683 |
Web of Science ID: |
000297757700012 |
URI: |
https://boris.unibe.ch/id/eprint/8070 (FactScience: 213528) |
Actions (login required)
 |
Edit item |